Author

Isabel Iborra colomino

LONG-TERM EXPERIENCE WITH USTEKINUMAB IN ULCERATIVE COLITIS PATIENTS: A REAL LIFE MULTICENTRE SPANISH COHORT
LONG-TERM EXPERIENCE WITH USTEKINUMAB IN ULCERATIVE COLITIS PATIENTS: A REAL LIFE MULTICENTRE SPANISH COHORT

Isabel Iborra colomino  et al.

USTEKINUMAB AND VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE IN CLINICAL PRACTICE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY
USTEKINUMAB AND VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE IN CLINICAL PRACTICE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY

Isabel Iborra colomino  et al.

REAL-LIFE EXPERIENCE OF THE EFFICACY, SAFETY AND PHARMACOKINETIC DATA OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INACTIVE INFLAMMATORY BOWEL DISEASE PATIENTS. RESULTS FROM THE ENEIDA REGISTRY
REAL-LIFE EXPERIENCE OF THE EFFICACY, SAFETY AND PHARMACOKINETIC DATA OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INACTIVE INFLAMMATORY BOWEL DISEASE PATIENTS. RESULTS FROM THE ENEIDA REGISTRY

Isabel Iborra colomino  et al.

IN PATIENTS WITH CROHN'S DISEASE MONITORING OF USTEKINUMAB LEVELS DURING INDUCTION CAN IDENTIFY EARLY INADEQUATE RESPONSE
IN PATIENTS WITH CROHN'S DISEASE MONITORING OF USTEKINUMAB LEVELS DURING INDUCTION CAN IDENTIFY EARLY INADEQUATE RESPONSE

Isabel Iborra colomino  et al.

HIV INFECTION IS ASSOCIATED WITH A LESS AGGRESSIVE PHENOTYPE OF INFLAMMATORY BOWEL DISEASE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY
HIV INFECTION IS ASSOCIATED WITH A LESS AGGRESSIVE PHENOTYPE OF INFLAMMATORY BOWEL DISEASE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY

Isabel Iborra colomino  et al.

IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)
IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)

Isabel Iborra colomino  et al.

Item 1 - 6 / 6
1